UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
__________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 28,
2007
AngioDynamics,
Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-50761
|
11-3146460
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
|
|
603
Queensbury Avenue, Queensbury, New
York 12804
|
|
(Address
of Principal Executive
Offices) (Zip
Code)
|
|
|
|
(518)
798-1215
|
|
(Registrant’s
telephone number, including area code)
|
Check
the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2 (b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4 (c))
|
Item
8.01. Other
Events.
On
August 28, 2007, AngioDynamics, Inc.
(the “Company”) announced that its Board of Directors elected Mr. Vincent Bucci
as its Chairman. Mr. Bucci joined the Company's Board in January 2007
when the Company acquired RITA Medical Systems, Inc. Mr. Bucci had
been Chairman of the RITA Medical Systems, Inc. board of directors since 2003
and a member of its board since 1994. The size of the Company's
Board of Directors remains unchanged, at nine members. Mr. Bucci succeeds Mr.
Paul Echenberg, who will remain on the Company's Board and continue to serve
on
the Compensation and Nominating and Corporate Governance
committees.
The
Company's August 28, 2007 press release, which is attached hereto as Exhibit
99.1 is incorporated herein by reference.
Item
9.01 – Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press
Release dated August 28, 2007.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ANGIODYNAMICS,
INC.
|
||
|
(Registrant)
|
||
|
Date:
August 30, 2007
|
By:
|
D.
Joseph Gersuk
|
|
Chief
Financial Officer
|
EXHIBIT
99.1
FOR
IMMEDIATE RELEASE
|
Company
Contact:
|
Investor
Relations Contacts:
|
Media
Contact:
|
|
|
AngioDynamics,
Inc.
|
EVC
Group, Inc.
|
EVC
Group, Inc.
|
|
|
D.
Joseph Gersuk, CFO
|
Jennifer
Beugelmans/Doug Sherk
|
Steve
DiMattia
|
|
|
(800)
772-6446 x1608
|
(646)
201-5447
|
(646)
201-5445
|
|
|
jgersuk@AngioDynamics.com
|
jbeugelmans@evcgroup.com
|
sdimattia@evcgroup.com
|
|
|
dsherk@evcgroup.com
|
ANGIODYNAMICS
ELECTS VINCENT BUCCI AS CHAIRMAN
OF
THE BOARD OF DIRECTORS
QUEENSBURY,
N.Y. August 28, 2007—AngioDynamics (NASDAQ: ANGO), a leading provider
of innovative medical devices used by interventional radiologists and surgeons
for the minimally invasive treatment of cancer and peripheral vascular disease,
announced today that its Board of Directors has elected Vincent Bucci as
its Chairman. Mr. Bucci joined the AngioDynamics Board in January 2007 when
AngioDynamics acquired RITA Medical Systems; he had been Chairman of the RITA
Medical Systems Board since 2003 and a Board member since 1994.
“Vin has
26 years of management and executive experience in health care regulatory
affairs and consulting, and an in-depth understanding of both the oncology
and
interventional businesses,” said Eamonn Hobbs, President and Chief Executive
Officer of AngioDynamics. “Vin’s extensive quality assurance and regulatory
experience will be a key asset to AngioDynamics as we continue to expand through
new product introductions and consider acquisitions. We are delighted
with his election and look forward to working with him in this
role.”
The
size of the AngioDynamics Board of Directors remains unchanged, at nine
members. Mr. Bucci succeeds Paul Echenberg, who will remain on the Board
and serve on the Compensation and Nominating and Corporate Governance
committees. Mr. Echenberg, 63, was elected Chairman in 2004, and has
served on the AngioDynamics Board since 1996.
"Vin
has brought an extremely high level of expertise, industry background and
leadership to the AngioDynamics Board. As the Company moves to its
next stage of growth, both organically and through potential acquisitions,
I
believe we will benefit from a Chairman with more domain experience and look
forward to working with Vin in his new role as Chairman of the Board,” said Mr.
Echenberg.
“During
Paul’s tenure as Chairman, AngioDynamics completed its initial public offering,
licensed the irreversible electroporation technology from Oncobionics, and
acquired
RITA Medical Systems, strengthening the Company’s position as a
leading provider of innovative products and solutions for the surgeon
and interventionist,” said Mr. Bucci. “This growing, dynamic Company owes a
great deal to his exceptional leadership and wise counsel. I
look forward to working with him and the rest of the Board to support
AngioDynamics’ growth and drive shareholder value.”
Mr.
Bucci, 53, is currently the president and founder of Health Policy Associates,
Inc., a research and consulting services company for the medical device,
biotechnology and pharmaceutical industries. Prior to founding Health
Policy Associates, Mr. Bucci spent 11 years with Pfizer Hospital Products Group,
most recently as Special Advisor on Health Policy. Mr. Bucci holds a
B.A. in political science from Bates College, and a J.D. and M.A. in Government,
both from Georgetown University.
About
AngioDynamics
AngioDynamics,
Inc. is a leading provider of innovative medical devices used by interventional
radiologists, surgeons, and other physicians for the minimally invasive
treatment of cancer and peripheral vascular disease. The Company's diverse
product line includes market-leading radiofrequency ablation systems, vascular
access products, angiographic products and accessories, dialysis products,
angioplasty products, drainage products, thrombolytic products, embolization
products and venous products.
Safe
Harbor
The
statements made in this document contain certain forward-looking statements
that
involve a number of risks and uncertainties. Words such as "expects," "intends,"
"anticipates," "plans," "believes," "seeks," "estimates," or variations of
such
words and similar expressions, are intended to identify such forward-looking
statements. Investors are cautioned that actual events or results may differ
from the Company's expectations. In addition to the matters described above,
the
ability of the Company to develop its products, future actions by the FDA or
other regulatory agencies, results of pending or future clinical trials, overall
economic conditions, general market conditions, market acceptance, foreign
currency exchange rate fluctuations, the effects on pricing from group
purchasing organizations and competition, as well as the risk factors listed
from time to time in the SEC filings of AngioDynamics, Inc., including but
not
limited to its Annual Report on Form 10-K for the year ended June 2, 2007,
may
affect the actual results achieved by the Company.
# # #